Tech Recruitment Goliath to Open Its First Office in Switzerland
12.1.2021 18:00:00 EET | Business Wire | Press release
UK staffing firm Frank Recruitment Group has today announced the opening of its latest location in Geneva, Switzerland.
The new office is the cloud recruitment company's eighth in Europe, bringing its total number of global hubs to 21.
Frank Recruitment Group, founded in Newcastle upon Tyne in 2006 with just three members of staff, now employs almost 2,000 people worldwide and is part of Tenth Revolution Group, the global leader in cloud talent solutions. The Swiss location will add a number of new team members to that headcount, with plans to create up to 50 jobs within five years.
The move will see Frank Recruitment Group further increase its reach in Europe and enable the firm to better support its growing global client base.
With the country's technology market expanding fast, and digitalisation and cloud migration at the top of every Swiss CIO's agenda, demand for IT professionals to support transformation is mounting.
"Our new Swiss base will allow us to offer better support to our clients and partners in the region, at a time when specialist technology recruitment consulting is more needed than ever," said Director of Sales Paul Hanley, who will be leading the new location.
"We want to replicate the success we’ve achieved in other global regions here in Switzerland by solidifying our position as the leaders in cloud tech staffing solutions, and continue to enable digital transformation by delivering the best permanent and contract tech talent to businesses that need it," Hanley said.
"I'm especially proud to be launching our Swiss office," said Zoë Morris, Frank Recruitment Group President. "2020 was a challenging year for the staffing industry, so it feels like a special achievement to be opening a new location and growing our business at this time. We feel very privileged to be able to serve this exciting market and create new jobs in the area in the process."
Hanley added, "Our launch team is packed with seasoned, multi-lingual staffing experts, all of whom have significant experience within the Swiss recruitment industry. Our focus is entirely on the tech market, and that will allow us to deliver the kind of dedicated, specialist expertise that's been missing in the Swiss market so far. I'm incredibly excited to get to work in the market, and make a real impact for both businesses and tech professionals in the area by connecting the right people with the right jobs."
At the new location, Frank Recruitment Group will initially launch its Nigel Frank, Mason Frank, and FRG Technology Consulting brands, which recruit for Microsoft, Salesforce, and emerging technology specialists, respectively.
The Swiss office is based at 14 Rue du Rhône, Geneva.
Note to editors:
ABOUT FRANK RECRUITMENT GROUP
Frank Recruitment Group is a division of Tenth Revolution Group, the world’s leading experts in cloud talent solutions. Founded in Newcastle upon Tyne, in 2006, Frank Recruitment Group creates and delivers highly sought-after professionals in some of the industry’s most skills-scarce ecosystems.
The company employs nearly 2,000 people across 20 offices, including Dallas, New York, Philadelphia, San Francisco, Tampa, Denver, Scottsdale, Charlotte, and Irvine in the US. EMEA and APAC are served by nine offices across the UK, Germany, the Netherlands, Spain, and locations in Singapore and Australia.
The group operates seven trading brands that each focus on a specific technology product: Jefferson Frank (AWS), Nigel Frank International (Microsoft Dynamics and Azure), Mason Frank International (Salesforce), Washington Frank (enterprise ERP), Anderson Frank (NetSuite), Nelson Frank (ServiceNow), and FRG Technology Consulting (Marketing Automation and emerging technologies).
Frank Recruitment Group was named one of Europe’s fastest-growing companies and received recognition as one of the UK’s top 100 private companies with the fastest-growing profits. The group plans to expand its outreach globally and attract more trainee recruiters in strategic hubs to meet demand for its services.
For more information, visit: www.frankgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005733/en/
Contact information
Media Enquiries:
Josie Middleton
T: +44 (0)191 338 7553
E: j.middleton@frankgroup.com
W: www.frankgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
